Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Lithium & Battery Tech ETF (LIT) vs Eli Lilly And Co (LLY) Price & Performance

Global X Lithium & Battery Tech ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Global X Lithium & Battery Tech ETF vs Eli Lilly And Co — how do they compare? Global X Lithium & Battery Tech ETF trades at $74.5, while Eli Lilly And Co trades at $1,214.74 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals.

LITLLY
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$91.62$1.24K
52-Week Low
$44.96$639.43
Market Cap
$1.10T
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Lithium & Battery Tech ETF

LIT trades at $74.01, up 2.21% today, with bullish technical signals from moving averages but caution from oscillators. The stock has doubled over the past year, driven by strong momentum in electric vehicles, energy storage, and semiconductors. Recent news highlights global EV sales growth and China's ambitious 30% fleet target by 2030, supporting the lithium and battery technology theme.

Outlook remains positive given structural EV adoption trends, though overbought RSI levels suggest near-term consolidation risk. Key risks include Chinese export controls, regulatory changes, and competitive pressures. Analyst sentiment is constructive with buy ratings emphasizing long-term growth catalysts in clean energy transition.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Lithium & Battery Tech ETF

LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.

Read more on LIT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY